Drucken

Woher ist?

  • [1] Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The Biology and Life-Cycle of Human Papillomaviruses. Vaccine. 2012;30 Suppl 5:F 55-70..
  • [2] Asiaf A, Ahmad ST, Mohammad SO, Zargar MA. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2014 May;23(3):206-24.
  • [3] Bosch FX, Tsu V, Vorsters A, Van Damme P, Kaned MA. Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. Vaccine. 2012;30 Suppl 5:F 1-11.
  • [4] Forman D, Martel Cd, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012;30 Suppl 5:F 12-23.
  • [5] Bruni L, Brotons M, Barrionuevo-Rosas L, Serrano B, Cosano R, Muñoz J, et al. Human Papillomavirus and Related Diseases in Germany. Summary Report: ICO Information Centre on HPV and Cancer (HPV Information Centre); 2014.
  • [6] Moscicki A-B, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the Natural History of Human Papillomavirus and Anogenital Cancers. Vaccine. 2012;30 Suppl 5.
  • [7] Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Muñoz J, et al. Human Papillomavirus and Related Diseases in Europe. Summary Report: ICO Information Centre on HPV and Cancer (HPV Information Centre); 2014.
  • [8] Mühlhauser I, Filz M. Screening auf Zervixkarzinom…Information zur Beratung von Frauen. Sonderbeilage arznei-telegramm. 2008;39(3).
  • [9] HPV-Infektion / präinvasive Läsionen des weiblichen Genitale: Prävention, Diagnostik und Therapie: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF); 2010.
  • [10] Krebs in Deutschland 2009/2010. 9. Ausgabe. Berlin: Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) 2013.
  • [11] Parkin D, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl. 3):S3/11-25.
  • [12] Batista C, Atallah Á, Saconato H, da Silva E. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database of Systematic Reviews. 2010(4):CD006562.
  • [13] Leitlinie der Deutschen STD-Gesellschaft in Zusammenarbeit mit der Deutschen Dermatologischen Gesellschaft und der Paul-Ehrlich-Gesellschaft. Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder von Genitale, Anus und Harnröhre. 2008 [cited 2014 8.7.]; Available from: http://www.dstig.de/images/059-001_S1_Condylomata_acuminata_und_andere_HPV-assoziierte_Krankheitsbilder_des_Genitale_und_der_Harnroehre_
    07-2006_07_2011.klein.pdf
  • [14] Up to date. Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics) 2013 [cited 2014 8.7.]; Available from: http://www.uptodate.com/patients
  • [15] Merkblatt des gemeinsamen Bundesausschusses vom 21. August 2008 zur Früherkennung von Gebärmutterhalskrebs. [cited 2014 11.7.]; Available from: http://www.g-ba.de/downloads/17-98-2633/2008-08-21-Merkblatt-Zervixkarzinom.pdf
  • [16] Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft e.V. (DKG) und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Diagnostik und Therapie des Zervixkarzinoms: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF); 2008.
  • [17] Guideline Syntheses: Screening for Cervical Cancer in Women at Average Risk. 2013 [cited 2014 11.7.]; Available from: http://www.guideline.gov/syntheses/synthesis.aspx?id=43606
  • [18] Public Health England. HPV primary screening in the NHS Cervical Screening Programme. NHS Cervical Screening Programme 2013 [cited 2014 11.7.]; Available from: http://www.cancerscreening.nhs.uk/cervical/hpv-primary-screening.html
  • [19] Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technology Assessment. 2014;18(23).
  • [20] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). [S13-03] Nutzenbewertung eines HPV-Tests im Primärscreening des Zervixkarzinoms - Rapid Report; 2014.
  • [21] Arbyn M, Kyrgiou M, Simoens C, Raifu A, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Bmj. 2008.
  • [22] Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. Vaccine. 2012 Nov 20;30 Suppl 5:F71-82.
  • [23] Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Muñoz J, et al. Human Papillomavirus and Related Diseases in World. Summary Report ICO Information Centre on HPV and Cancer (HPV Information Centre); 2014.
  • [24] Ständige Impfkommission (STIKO) am Robert Koch Institut. Impfkalender 2014. Epidemiologisches Bulletin Nr.34 vom 24.8.2014. 2014 [cited 2014 24.9.]; Available from: http://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Aktuelles/
    Impfkalender.html
  • [25] GlaxoSmithKline Biologicals. Cervarix® : EPAR - Product Information (Zusammenfassung der Merkmale des Arzneimittels) 2014 [cited 2014 14.7.]; Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf
  • [26] sanofi pasteur MSD. Fachinformation Gardasil®. 2014 [cited 2014 14.7.]; Available from: http://www.impfservice.de/fileadmin/user_upload/pdfs/Fachinformationen/FI-Gardasil_06-2014_v2_RLFI-5466.pdf
  • [27] Paul Ehrlich Institut. Liste zugelassener Impfstoffe gegen Gebärmutterhalskrebs (Infektionen durch das Humane Papillomvirus - HPV). 2014 [cited 2014 14.7.]; Available from: http://www.pei.de/DE/arzneimittel/impfstoff-impfstoffe-fuer-den-menschen/hpv-humane-papillomviren-gebaermutterhalskrebs/hpv-humane-papillomviren-gebaermutterhalskrebs-node.html
  • [28] Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012 Nov 20;30 Suppl 5:F123-38.
  • [29] Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010 Mar 3;102(5):325-39.
  • [30] Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.[Erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. Lancet Oncol. 2012 Jan;13(1):89-99.
  • [31] European Medicines Agency. Gardasil-H-C-703-II-26 : EPAR - Assessment report - Variation. 2010 [cited 2014 22.7.]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000703/WC500096580.pdf
  • [32] Skinner S, Szarewski A, Romanowski B, Garland S, Lazcano-Ponce E, Salmerón J, et al. for the VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014 Sep 1;pii: S0140-6736(14)60920-X. doi: 10.1016/S0140-6736(14)60920-X. [Epub ahead of print].
  • [33] Miltz A, Price H, Shahmanesh M, Copas A, Gilson R. Systematic Review and Meta-Analysis of L1-VLP-Based Human Papillomavirus Vaccine Efficacy against Anogenital Pre-Cancer in Women with Evidence of Prior HPV Exposure. PLoS ONE. 2014;9(3):e90348.
  • [34] Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol. 2009 Feb;113(2 Pt 2):550-2.
  • [35] Miksis S. A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of human papillomavirus infections. J Obstet Gynecol Neonatal Nurs. 2008 May-Jun;37(3):329-37.
  • [36] Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. N Engl J Med. 2006;354:2645-54.
  • [37] Manhart L, Koutsky L. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A metaanalysis. Sex Transm Dis. 2002;29(11):725-35.
  • [38] Hogewoning C, Bleeker M, van den Brule A, Voorhorst F, Snijders P, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer. 2003;107(5):811-6.
  • [39] Maglione M, Gidengil C, Das L, Raaen L, Smith A, Chari R, et al. Safety of Vaccines Used for Routine Immunization in the United States Evidence Report/Technology Assessment No. 215. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.): AHRQ Publication No. 14-E002-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
  • [40] Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013 Nov 1;208(9):1391-6.
  • [41] Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011 Jun 28;105(1):28-37.
  • [42] GlaxoSmithKline Vaccine HPVSG, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009 Dec 12;374(9706):1975-85.
  • [43] Naud P, Roteli-Martins C, De Carvalho N, Teixeira J, de Borba P, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):[Epub ahead of print].
  • [44] Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer. 2013 Jun 15;132(12):2833-8.
  • [45] Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia—Nationwide Follow-up of Young Danish Women. J Natl Cancer Inst. 2014;106(3):djt460.
  • [46] Mahmud S, Kliewer E, Lambert P, Bozat-Emre S, Demers A. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol. 2014;32(5):438-43.
  • [47] Brotherton J, Fridman M, May C, Chappell G, Saville A, Gertig D. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-92.
  • [48] Gertig D, Brotherton J, Budd A, Drennan K, Chappell G, Saville A. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227.
  • [49] Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, et al. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer. 2012 Dec 15;131(12):2832-8.
  • [50] Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.[Erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. Lancet Oncol. 2012 Jan;13(1):100-10.
  • [51] Malagon T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Oct;12(10):781-9.
  • [52] Giuliano A, Anic G, Nyitray A. Epidemiology and pathology of HPV disease in males. Gynecol Oncol. 2010;117(2 Suppl):S15-9.
  • [53] Garland SM. Prevention strategies against human papillomavirus in males. Gynecol Oncol. 2010 May;117(2 Suppl):S20-5.
  • [54] Gross G, Becker N, Brockmeyer N, et. al. Impfprävention HPV-assoziierter Neoplasien. S3 Leitlinie: AWMF; 2013.
  • [55] European Medicines Agency. Gardasil-H-C-703-WS-29 : EPAR - Assessment report - Variation 2011 [cited 2014 30.7.]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000703/WC500118054.pdf